TY - JOUR T1 - Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients JF - medRxiv DO - 10.1101/2021.01.26.21250013 SP - 2021.01.26.21250013 AU - Pei Meng AU - Anna A. Rybczynska AU - Jiacong Wei AU - Miente Martijn Terpstra AU - Wim Timens AU - Ed Schuuring AU - T. Jeroen N. Hiltermann AU - Harry J.M. Groen AU - Anthonie J. van der Wekken AU - Anke van den Berg AU - Klaas Kok Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/28/2021.01.26.21250013.abstract N2 - Background Nowadays, the detection of therapy-guiding aberrations such as EGFR mutations and ALK fusion genes in tumor tissue is common practice for lung cancer patients. The aim of this study is to explore the feasibility of detecting common therapy-guiding aberrations in RNA isolated from platelets.Methods We applied a single primed enrichment-based targeted next generation sequencing (NGS) approach on 10 platelet RNA samples isolated from patients with active disease. In parallel, we applied RNA-based ddPCR focusing on EGFR p.(T790M), p.(L858R) and E19del, on KRAS codon 12 and 13 and on ALK-EML4/KIF5B fusions on 22 platelet RNA samples from patients with tumors known to harbor one of these drivers. For 11 cases ddPCR analysis of circulating cell free (cf)DNA from the same blood sample was performed in parallel.Results Despite having good quality NGS data, none of the variants detected in the tumor biopsy were observed in platelet-derived RNA samples. Using the more sensitive ddPCR, we detected known aberrations in three of 22 platelet-derived RNA samples. EGFR mutant droplets were not observed in any of the seven platelet samples, while these mutations were detected in three of six cfDNA samples of which five were extracted from the same blood sample. KRAS mutant droplets were detected in three out of nine platelet RNA samples with fractional abundances of 0.07%, 0.11% and 0.55%. Analysis of five cfDNA samples from the same blood samples revealed KRAS-mutant droplets in four of them. Two of the four corresponding platelet RNA samples were also positive for mutant KRAS. No ALK fusion droplets were detected in seven platelet derived RNA samples.Conclusions The level of tumor-derived RNA transcripts in platelets of non-small cell lung cancer patients was too low to be measured reliably for clinically relevant alterations in EGFR, KRAS and ALK fusion gene transcripts.Competing Interest StatementEd Schuuring has performed lectures for Bio-Rad, Novartis, Roche, Biocartis, Illumina, Pfizer, AstraZeneca, and Agena Bioscience, is consultant in advisory boards for AstraZeneca, Roche, Pfizer, Novartis, Bayer, Lilly, BMS, Amgen, BioCartis, Illumina, Agena Bioscience and MSD/Merck, and received research grants from Pfizer, Biocartis, Agena Bioscience, BMS, Bio-Rad, Roche, Boehringer Ingelheim. Wim Timens reports fees to Institution for lectures or consultancy from Roche Diagnostics / Ventana, Merck Sharp Dohme, Bristol-Myers-Squibb, and AbbVie, outside the submitted work. Harry J M Groen reports grants from Boehringer-Ingelheim, Takeda, BMS, Novartis, Merck outside the submitted work. Anthonie van der Wekken has performed lectures for Lilly, Boehringer-Ingelheim, Pfizer, AstraZeneca, Roche (diagnostics) and Takeda, is consultant in advisory boards for Lilly, Boehringer-Ingelheim, Pfizer, AstraZeneca, Roche (diagnostics), Takeda and Janssen, received grants from Boehringer-Ingelheim, Pfizer, AstraZeneca, Roche and Takeda all outside the submitted work. Jeroen Hiltermann reports grants from AstraZeneca, Roche, BMS, outside the submitted work. Funding StatementThis research was funded by the Dutch Cancer Society Grant: KWF grant (RUG2015-8044).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study ethics was approved by the OncoLifeS biobank committee (Biobank of cancer in UMCG). The biobank was approved by the UMCG research ethics committee. The study was conducted in accordance with the 1964 Helsinki declaration.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. ER -